ATA Action 就 FDA 生成式 AI 医疗器械监管提交意见：双轴风险与 PCCP
ATA Action Responds to FDA on Generative AI Medical Devices: Two-Axis Risk, PCCPs, and Manufacturer Accountability
远程医疗协会给 FDA 交了生成式 AI 医疗器械的监管意见，讲了怎么分级风险、怎么用 PCCP 管模型更新，做医疗 AI 的可以看看。
ATA Action（美国远程医疗协会的倡导分支）向 FDA 器械与放射健康中心（CDRH）主任 Michelle Tarver 提交了关于 Docket No. FDA-2026-N-7874 的正式意见，该文件针对生成式 AI 医疗器械的监管讨论稿征集反馈。意见提出按双轴框架评估风险，并讨论 PCCP（预定变更控制计划）在生成式 AI 器械更新中的适用性。意见还强调制造商对生成式 AI 器械输出负有问责责任。
ATA Action Responds to FDA on Generative AI Medical Devices: Two-Axis Risk, PCCPs, and Manufacturer Accountability
What You Should Know ATA Action, the advocacy affiliate of the American Telemedicine Association (ATA), formally submitted comments to Dr. Michelle Tarver, M.D., Ph.D., Director of the FDA’s Center for Devices and Radiological Health (CDRH), addressing Docket No. FDA-2026-N-7874 (Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback). Endorses ... Read More
